Related Experiment Video
Updated: Aug 12, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk?
1Division of Retrovirology, Walter Reed Army Institute of Research, Rockville, Maryland 20850.
Abstract:
Antibody-dependent enhancement is a general in vitro property of enveloped viruses. In certain circumstances, antibody-dependent enhancement is a bona fide pathophysiologic mechanism in vivo. There are several examples of virus disease of humans and animals in which incomplete or partial immunity can lead to enhanced infection and/or disease. In some cases, this appears to be attributable to antibody-dependent enhancement. Conversely, there are several examples of viruses for which in vitro antibody-dependent enhancement has been demonstrated, but for which vaccines have been used safely in millions of persons for decades. Finally, antibody-dependent enhancement of HIV is a genuine concern. However, to date there is no direct clinical, experimental, or epidemiological evidence that HIV enhancement can be operative in vivo. Such evidence should be actively sought.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Cross-reactivity
Vaccinations

